NL-OMON56584尚未招募不适用
Effect of 4 weeks of oral D. piger on safety, pharmacokinetics and ethanol metabolism in overweight individuals (2023) - PIGER
Amsterdam UMC0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Increased waist circumference (>102 cm men, 88>cm women)
- •- Insulin resistance (HOMA-IR >2,5)
- •- 18-70 years
排除标准
- •- Use of systemic medication (except for paracetamol), including proton pump
- •inhibitors, antibiotics and pro-/prebiotics in the past three months or during
- •the study period.
- •- A history of a cardiovascular event
- •- A history of cholecystectomy
- •- Overt untreated gastrointestinal disease or abnormal bowel habits
- •- Liver enzymes>2.5*fold higher than the upper limit of normal range
- •- Alcohol abuse
研究者
相似试验
进行中（未招募）
不适用
A 12-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.Agitation and Aggression in Moderate to severe Alzheimer's Disease.EUCTR2012-005524-15-ESElan Pharma International Ltd400
进行中（未招募）
1 期
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.EUCTR2012-005524-15-GBElan Pharma International Ltd400
进行中（未招募）
1 期
Safety of continued use of oral docetaxel in patients with advanced solid types of cancerEUCTR2017-000347-41-NLModra Pharmaceuticals BV45
招募中
2 期
Exploratory study on the safety of oral administration of dapagliflozin for renal dysfunction in patients with unilateral nephrectomyChronic renal failureJPRN-jRCT1031220661Yamada Daisuke10
已完成
不适用
Safety and efficacy of 4 difference direct oral anticoagulants, dabigatran, rivaroxaban, apixaban and edoxaban in real-world clinical practice: a single center prospective all-comer registrynon-valvular atrial fibrillationJPRN-UMIN000033283Department of Cardiology, Osaka Police Hospital2,000